Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 4/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512132 | 1.00 | CTSS (0.50) | CTSSCTSKNTMT1CACNA1BCHRM3 | |
| SCHEMBL8512124 | 1.00 | CTSS (0.50) | CTSSCTSKNTMT1CACNA1BCHRM3 | |
| SCHEMBL2485594 | 0.91 | CHRM3 (0.52) | CTSSCTSKCHRM3KLK7KLK5 | |
| SCHEMBL2996529 | 0.91 | CHRM3 (0.52) | CTSSCTSKCHRM3KLK7KLK5 | |
| SCHEMBL2485597 | 0.91 | CHRM3 (0.52) | CTSSCTSKCHRM3KLK7KLK5 | |
| SCHEMBL8511307 | 0.88 | YAP1 (0.55) | CHRM3KLK7KLK5ACE | |
| SCHEMBL8511309 | 0.88 | YAP1 (0.55) | CHRM3KLK7KLK5ACE | |
| SCHEMBL8511306 | 0.88 | YAP1 (0.55) | CHRM3KLK7KLK5ACE | |
| SCHEMBL9290003 | 0.85 | CACNA1B (0.57) | CACNA1BCHRM3 | |
| SCHEMBL193077 | 0.80 | CACNA1B (0.59) | CTSSCTSKCACNA1BACEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643295-B1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| EP-2643295-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | Chiesi Farmaceutici S.p.A. (IT) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069275-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | WO | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, GLRB, CHRNG | CTSS 4443/4885CTSK 3906/4885NTMT1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.